Affinity Wealth Management’s Taysha Gene Therapies TSHA Stock Holding History

Affinity Wealth Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.93M	Buy	+576,808	New	+$3.41M	0.51%	36

Other funds holding TSHA

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Red Reef Advisors Boca Raton, Florida $108M AUM

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return

Lee Financial Dallas, Texas $783M AUM 23.98% 1-Year Est. Return

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Affinity Wealth Management's TSHA Position: Q2 2026 in Review

Affinity Wealth Management opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 576,808 shares worth $3.93M. The stake represents 0.51% of the portfolio and ranks #36 among its holdings.

17 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Affinity Wealth Management held 576,808 shares of Taysha Gene Therapies worth $3.93M as of Q2 2026.
Taysha Gene Therapies was a new Affinity Wealth Management position in Q2 2026.
Taysha Gene Therapies made up 0.51% of Affinity Wealth Management's portfolio in Q2 2026, its #36 holding.
17 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Affinity Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.